Management of localized, infradiaphragmatic Hodgkin’s disease: Experience of a rare clinical presentation at St. Bartholomew’s Hospital

  • M. S. Dorreen
  • P. F. M. Wrigley
  • A. E. Jones
  • W. S. Shand
  • A. G. Stansfeld
  • T. A. Lister
Part of the Developments in Oncology book series (DION, volume 32)


Hodgkin’s disease (HD) confined to infradiaphragmatic sites is uncommon [1–5] and relatively little information regarding the prognosis in this substage is available. An analysis of the outcome of treatment of previously untreated patients with Stages IA-IIB infradiaphragmatic HD referred to St. Bartholomew’s hospital, over a 14 year period, is presented.


Mycosis Fungoides Pulmonary Sarcoidosis Splenic Involvement Lymphocyte Predominance Rare Clinical Presentation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Fuller LM (1966). Results of large volume irradiation in the management of Hodgkin’s disease and malignant lymphomas originating in the abdomen. Radiology 87: 1058–1064.PubMedGoogle Scholar
  2. 2.
    Fuller LM, Gamble JF, Ibrahim E et al. (1973). Stage II Hodgkin’s disease. Significance of mediastinal and nonmediastinal presentations. Radiology 109: 429–435.PubMedGoogle Scholar
  3. 3.
    Krikorian JG, Portlock CS, Rosenberg SA and Kaplan HS (1976). Hodgkin’s disease, Stages I and II occurring below the diaphragm. Cancer 43: 1866–1871.CrossRefGoogle Scholar
  4. 4.
    Mauch PM, Lewin A and Hellman S (1982). The role of irradiation in the treatment of Stage I-II Hodgkin’s disease. In: Rosenberg SA and Kaplan HS (Eds.). Malignant Lymphomas: Etiology, Immunology, Pathology, Treatment, pp. 453–467. New York: Academic Press.Google Scholar
  5. 5.
    Mauch PM, Greenberg H, Lewin A et al. (1983). Prognostic factors in patients with sub-diaphragmatic Hodgkin’s disease. J Haematol Oncol 1: 205–214.CrossRefGoogle Scholar
  6. 6.
    Lukes RJ, Craver LF, Hall TC et al. (1966). Report of the Nomenclature Committee. Cancer Res 26: 1311.Google Scholar
  7. 7.
    Carbone PP, Kaplan HS, Musshoff K et al. (1971). Report of the Committee on Hodgkin’s Disease Staging. Cancer Res 31: 1860–1861.PubMedGoogle Scholar
  8. 8.
    Sutcliffe SBJ, Wrigler PFM, Smyth JF et al. (1976). Intensive investigation in the management of Hodgkin’s disease. Brit Med J 2: 1343–1347.PubMedCrossRefGoogle Scholar
  9. 9.
    Timothy AR, Sutcliffe SBJ, Stansfeld AG et al. (1978). Radiotherapy in the treatment of Hodgkin’s disease. Brit Med J 1: 1246–1249.PubMedCrossRefGoogle Scholar
  10. 10.
    Sutcliffe SBJ, Wrigley PFM, Peto J et al. (1978). MVPP chemotherapy regime for advanced Hodgkin’s disease. Brit Med J 1: 679–683.PubMedCrossRefGoogle Scholar
  11. 11.
    Kaplan E and Meier P (1958). Nonparametric estimation from incomplete observations. Amer Stat Assoc J 53: 457–480.CrossRefGoogle Scholar
  12. 12.
    Peto R, Pike MC, Armitage P et al. (1977). Design and analysis of randomised clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Brit J Cancer 35: 1–35.PubMedCrossRefGoogle Scholar
  13. 13.
    Pene F, Henry-Amar M, Le Bourgeois JP et al. (1980). A study of relapse and course of 153 cases of Hodgkin’s disease (clinical Stages I and II) treated at the Institute Gustave-Roussy from 1963 to 1970 with radiotherapy alone or with adjuvant monochemotherapy. Cancer 46: 2131–2141.PubMedCrossRefGoogle Scholar
  14. 14.
    Kaplan HS (1980). Hodgkin’s disease, 2nd ed. Cambridge: Harvard University Press.Google Scholar
  15. 15.
    Hoppe RT, Coleman CN, Cox RS et al. (1982). The management of Stage I-II Hodgkin’s disease with irradiation alone or combined modality therapy: The Stanford experience. Blood 59: 455–465.PubMedGoogle Scholar
  16. 16.
    Fuller LM, Madoc-Jones H, Hagemeister FB et al. (1980). Further follow-up of results of treatment in 90 laparotomy-negative Stage I and II Hodgkin’s disease patients: Significance of mediastinal and non-mediastinal presentations. Int J Radiat Oncol Biol Phys 6: 799–808.PubMedCrossRefGoogle Scholar
  17. 17.
    Dorreen MS, Plowman PN, Laidlow J et al. (1984). The management of Stage II supra-diaphragmatic Hodgkin’s disease at St. Bartholomew’s Hospital: A retrospective review of 114 previously untreated patients over 14 years. Cancer (in press).Google Scholar
  18. 18.
    Hoppe RT, Rosenberg SA, Kaplan HS and Cox RS (1980). Prognostic factors in pathological Stage IIA Hodgkin’s disease. Cancer 46: 1240–1246.PubMedCrossRefGoogle Scholar
  19. 19.
    Hoppe RT, Cox RS, Rosenberg SA and Kaplan HS (1982). Prognostic factors in pathologic Stage III Hodgkin’s disease. Cancer Treat Rep 66: 743–749.PubMedGoogle Scholar
  20. 20.
    Lister TA, Dorreen MS, Faux M et al. (1983). The treatment of Stage IIIA Hodgkin’s disease. J Clin Oncol 1: 745–749.PubMedGoogle Scholar
  21. 21.
    Westling P (1965). Studies of the prognosis in Hodgkin’s disease. Acta Radiol (Suppl) 245: 5–125.Google Scholar
  22. 22.
    Ihde DC, DeVita VT (1975). Osteonecrosis of the femoral heads in patients with lymphoma treated with intermittent combination chemotherapy. Cancer 36: 1585–1588.PubMedCrossRefGoogle Scholar
  23. 23.
    Timothy AR, Tucker AK, Park WM and Cannell LB (1978). Osteonecrosis in Hodgkin’s disease. Brit J Radiol 51: 328–332.PubMedCrossRefGoogle Scholar

Copyright information

© Martinus Nijhoff Publishers, Boston 1985

Authors and Affiliations

  • M. S. Dorreen
    • 1
  • P. F. M. Wrigley
    • 1
  • A. E. Jones
    • 1
  • W. S. Shand
    • 1
  • A. G. Stansfeld
    • 1
  • T. A. Lister
    • 1
  1. 1.ICRF Department of Medical OncologySt. Bartholomew’s HospitalLondonUK

Personalised recommendations